Balcells ME, Rojas L, Le Corre N, et al. - Researchers conducted an open-label, single-center randomized clinical trial with the aim to examine the efficacy and safety of early convalescent plasma (CP) therapy in COVID-19 progression. Randomization was performed of a total of 58 patients (mean age, 65.8 years; 50% male) who were hospitalized within the first 7 days of COVID-19 symptom onset, presenting risk factors for illness progression and not on mechanical ventilation. Immediate CP (early plasma group) vs no CP unless developing prespecified criteria of deterioration (deferred plasma group) were the included interventions. The arms were provided additional standard treatment. Findings yielded no evidence of benefit of immediate addition of CP therapy in the early stages of COVID-19 in terms of mortality, length of hospitalization, or mechanical ventilation requirement when compared with its use only in case of patient deterioration.